C21 Investments Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
C21 Investments has been growing earnings at an average annual rate of 57.2%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 0.5% per year.
Key information
57.2%
Earnings growth rate
70.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 0.5% |
| Return on equity | -1.0% |
| Net Margin | -1.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Some C21 Investments Inc. (CSE:CXXI) Shareholders Look For Exit As Shares Take 26% Pounding
Nov 12
Subdued Growth No Barrier To C21 Investments Inc.'s (CSE:CXXI) Price
Sep 12C21 Investments Inc.'s (CSE:CXXI) 30% Share Price Surge Not Quite Adding Up
May 12A Look At The Intrinsic Value Of C21 Investments Inc. (CSE:CXXI)
May 01Some Confidence Is Lacking In C21 Investments Inc. (CSE:CXXI) As Shares Slide 27%
Mar 09Is C21 Investments (CSE:CXXI) A Risky Investment?
Sep 04These 4 Measures Indicate That C21 Investments (CSE:CXXI) Is Using Debt Reasonably Well
Mar 21These 4 Measures Indicate That C21 Investments (CSE:CXXI) Is Using Debt Reasonably Well
Nov 29C21 Investments Inc. (CSE:CXXI) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Oct 12A Look At The Fair Value Of C21 Investments Inc. (CSE:CXXI)
Apr 22Does C21 Investments (CSE:CXXI) Have A Healthy Balance Sheet?
Mar 22C21 Investments' (CSE:CXXI) Solid Earnings May Rest On Weak Foundations
Oct 05We Think C21 Investments (CSE:CXXI) Can Stay On Top Of Its Debt
Sep 03C21 Investments (CSE:CXXI) Seems To Use Debt Quite Sensibly
Mar 07Revenue & Expenses Breakdown
How C21 Investments makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 27 | 0 | 6 | 0 |
| 31 Jan 24 | 28 | -3 | 7 | 0 |
| 31 Oct 23 | 29 | -3 | 6 | 0 |
| 31 Jul 23 | 29 | -2 | 6 | 0 |
| 30 Apr 23 | 29 | 0 | 6 | 0 |
| 31 Jan 23 | 29 | 1 | 6 | 0 |
| 31 Oct 22 | 30 | 3 | 6 | 0 |
| 31 Jul 22 | 30 | 6 | 6 | 0 |
| 30 Apr 22 | 32 | 8 | 6 | 0 |
| 31 Jan 22 | 33 | 12 | 6 | 0 |
| 31 Oct 21 | 32 | 8 | 8 | 0 |
| 31 Jul 21 | 33 | 8 | 9 | 0 |
| 30 Apr 21 | 34 | 2 | 8 | 0 |
| 31 Jan 21 | 33 | -5 | 9 | 0 |
| 31 Oct 20 | 36 | -22 | 7 | 0 |
| 31 Jul 20 | 38 | -29 | 7 | 0 |
| 30 Apr 20 | 38 | -31 | 10 | 0 |
| 31 Jan 20 | 38 | -33 | 11 | 0 |
| 31 Oct 19 | 30 | -23 | 9 | 0 |
| 31 Jul 19 | 20 | -21 | 10 | 0 |
| 30 Apr 19 | 10 | -26 | 14 | 0 |
| 31 Jan 19 | 3 | -24 | 12 | 0 |
| 31 Oct 18 | 0 | -12 | 11 | 0 |
| 31 Jul 18 | 0 | -9 | 9 | 0 |
| 30 Apr 18 | 0 | -2 | 1 | 0 |
| 31 Jan 18 | 0 | -1 | 1 | 0 |
| 31 Oct 17 | 0 | 0 | 0 | 0 |
| 31 Jul 17 | 0 | 0 | 0 | 0 |
| 30 Apr 17 | 0 | 0 | 0 | 0 |
| 31 Jan 17 | 0 | 0 | 0 | 0 |
| 31 Oct 16 | 0 | 0 | 0 | 0 |
| 31 Jul 16 | 0 | 0 | 0 | 0 |
| 30 Apr 16 | 0 | 0 | 0 | 0 |
| 31 Jan 16 | 0 | 0 | 0 | 0 |
| 31 Oct 15 | 0 | 0 | 0 | 0 |
| 31 Jul 15 | 0 | 0 | 0 | 0 |
| 30 Apr 15 | 0 | 0 | 0 | 0 |
| 31 Jan 15 | 0 | 0 | 0 | 0 |
| 31 Oct 14 | 0 | 0 | 0 | 0 |
| 31 Jul 14 | 0 | 0 | 0 | 0 |
| 30 Apr 14 | 0 | 0 | 0 | 0 |
Quality Earnings: CXXI is currently unprofitable.
Growing Profit Margin: CXXI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CXXI is unprofitable, but has reduced losses over the past 5 years at a rate of 57.2% per year.
Accelerating Growth: Unable to compare CXXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CXXI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: CXXI has a negative Return on Equity (-1%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 22:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
C21 Investments Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|